Main Menu
Take Action
Menu

Public Comments

C4IP Comments RE: Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights, 2/6/2024

C4IP Comments RE: Implications of Access and Benefit Sharing (ABS) Commitments/Regimes and Other Proposed Commitments in the WHO Pandemic Agreement, 1/30/2024

C4IP Comments RE: Special 301 Review, 1/30/2024

C4IP Comments RE: PTO-C-2023-0019, 1/22/2024

C4IP Comments RE: PTO-C-2023-0034, 11/6/2023

C4IP Comments RE: 7/31 NIH Tech Transfer Workshop, 7/26/2023

C4IP Comments RE: PAHPA, 7/10/2023

C4IP Response RE: PTO–P–2020–0022, 6/20/2023

C4IP Public Interest Comments RE: ITC Inv. No. 337-TA-1276 - Certain Light-Based Physiological Measurement Devices and Components Thereof, 6/5/2023

C4IP Written Submission for Inv. No. 332-596, 4/26/2023

Public Comments on European Commission Draft SEP Regulation, 4/19/2023

C4IP Response to CMS Solicitation of Comments Concerning Initial Guidance on the Inflation Reduction Act’s (IRA) Medicare Drug Negotiation Program, 4/14/2023

C4IP Post-Hearing Brief RE: U.S. International Trade Commission Investigation No. 332-596: COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities, 3/29/23

C4IP Testimony RE: U.S. International Trade Commission Investigation No. 332-596: COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities, 3/29/23

C4IP Response to RFC on Joint USPTO-FDA Collaboration Initiatives, 3/10/2023

C4IP response to ITC Inv. No. 337-TA-1276 - Certain Light-Based Physiological Measurement Devices and Components Thereof, 2/23/2023

C4IP response to USPTO RFC on Initiatives to Ensure the Robustness and Reliability of Patent Rights, 1/31/2023

Scroll to Top